RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.240
+0.040 (3.33%)
At close: Jul 31, 2025, 4:00 PM
1.260
+0.020 (1.61%)
After-hours: Jul 31, 2025, 7:29 PM EDT
RenovoRx Revenue
RenovoRx had revenue of $197.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $240.00K. In the year 2024, RenovoRx had annual revenue of $43.00K.
Revenue (ttm)
$240.00K
Revenue Growth
n/a
P/S Ratio
136.32
Revenue / Employee
$24,000
Employees
10
Market Cap
45.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 57.37B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
RNXT News
- 3 days ago - RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors - Business Wire
- 17 days ago - RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET - Business Wire
- 2 months ago - RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - Business Wire
- 3 months ago - U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire
- 3 months ago - RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - Business Wire
- 3 months ago - Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial - Business Wire